Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AEG35156 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pharmascience
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
**AEG35156 + paclitaxel** is a combination therapy composed of AEG35156 (also known as GEM640), an antisense oligonucleotide targeting X-linked inhibitor of apoptosis protein (XIAP), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. AEG35156 is designed to decrease XIAP mRNA and protein expression, promoting apoptosis in cancer cells. Paclitaxel promotes cell death by stabilizing tubulin and preventing microtubule disassembly during cell division. This combination has been primarily investigated for advanced and metastatic breast cancer in clinical trials, hypothesizing increased cancer cell apoptosis through dual mechanisms: XIAP inhibition and mitotic arrest by microtubule stabilization[3][6][8].
- Other names
- AEG35156AEG-35156AEG 35156GEM640GEM-640GEM 640paclitaxel
02
Targets
XIAPTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AEG35156 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AEG35156 + paclitaxel.